Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2021 Update

Pages: 4011 Published: December 30, 2021 Report Code: GMDGDHC13204IDB

Acute myelocytic leukemia (AML), also known as acute myelogenous leukemia is a type of cancer that affects the blood and the bone marrow. Immature white blood cells accumulate in the bone marrow thus blocking the production of normal blood cells. These cells further enter the bloodstream and spread to the other parts of the body. Symptoms of AML include fatigue, fever, bleeding, breathing problems, and weight loss. The predisposing factors involved are exposure to radiation or chemicals and smoking. Treatment includes chemotherapy, transfusions, transplant, and surgery.

The Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Drugs in Development market research report provides an overview of the Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) and features dormant and discontinued projects.

What are the targets of the AML pipeline drugs market?

Some of the targets of the AML pipeline drugs market are Receptor Type Tyrosine Protein Kinase FLT3, Cells Expressing Interleukin 3 Receptor Subunit Alpha, Cells Expressing Myeloid Cell Surface Antigen CD33, Cells Expressing C Type Lectin Domain Family 12 Member A, Leukocyte Surface Antigen CD47, CD3, Cyclin Dependent Kinase 9, DNA, Lysine Specific Histone Demethylase 1A (BRAF35 HDAC Complex Protein BHC110 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or [Histone H3]-Dimethyl-L-Lysine, and B Cell Lymphoma 2.

AML pipeline drugs market, by targets

AML pipeline drugs market, by targets

For more target insights, download a free report sample

What are the mechanisms of action of the AML pipeline drugs market?

Some of the mechanisms of action of the AML pipeline drugs market are Receptor Type Tyrosine Protein Kinase FLT3 Inhibitor, Cytotoxic To Cells Expressing Interleukin 3 Receptor Subunit Alpha, Cytotoxic To Cells Expressing Myeloid Cell Surface Antigen CD33, Cytotoxic To Cells Expressing C Type Lectin Domain Family 12 Member A, Leukocyte Surface Antigen CD47 Inhibitor, CD3 Agonist, Cyclin Dependent Kinase 9 Inhibitor, Lysine Specific Histone Demethylase 1A (BRAF35 HDAC Complex Protein BHC110 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or [Histone H3]-Dimethyl-L-LysineInhibitor, B Cell Lymphoma 2 Inhibitor, and Bromodomain Containing Protein 4 Inhibitor.

AML pipeline drugs market, by mechanisms of action

AML pipeline drugs market, by mechanisms of action

For more mechanisms of action insights, download a free report sample

What are the routes of administration in the AML pipeline drugs market?

Some of the routes of administration in the AML pipeline drugs market are oral, intravenous, parenteral, subcutaneous, intratumor, topical, intradermal, intralesional, inhalational, and intraperitoneal.

AML pipeline drugs market, by routes of administration

AML pipeline drugs market, by routes of administration

For more routes of administration insights, download a free report sample

What are the molecule types in the AML pipeline drugs market?

The molecule types in the AML pipeline drugs market are small molecule, gene-modified cell therapy, monoclonal antibody, cell therapy, monoclonal antibody conjugated, fusion protein, synthetic peptide, subunit vaccine, antisense oligonucleotide, and aptamer.

AML pipeline drugs market, by molecule types

AML pipeline drugs market, by molecule types

For more molecule type insights, download a free report sample

Which are the key companies in the AML pipeline drugs market?

Some of the key companies in the AML pipeline drugs market are Bristol-Myers Squibb Co, Les Laboratoires Servier SAS, Novartis AG, Pfizer Inc, AbbVie Inc, Ascentage Pharma Group International, Daiichi Sankyo Co Ltd, Johnson & Johnson, AstraZeneca Plc, and CSPC Pharmaceutical Group Ltd.

AML pipeline drugs market, by key companies

AML pipeline drugs market, by key companies

To know more about key companies, download a free report sample

Market report scope

Targets Receptor Type Tyrosine Protein Kinase FLT3, Cells Expressing Interleukin 3 Receptor Subunit Alpha, Cells Expressing Myeloid Cell Surface Antigen CD33, Cells Expressing C Type Lectin Domain Family 12 Member A, Leukocyte Surface Antigen CD47, CD3, Cyclin Dependent Kinase 9, DNA, Lysine Specific Histone Demethylase 1A (BRAF35 HDAC Complex Protein BHC110 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or [Histone H3]-Dimethyl-L-Lysine, and B Cell Lymphoma 2
Mechanisms of Action Receptor Type Tyrosine Protein Kinase FLT3 Inhibitor, Cytotoxic To Cells Expressing Interleukin 3 Receptor Subunit Alpha, Cytotoxic To Cells Expressing Myeloid Cell Surface Antigen CD33, Cytotoxic To Cells Expressing C Type Lectin Domain Family 12 Member A, Leukocyte Surface Antigen CD47 Inhibitor, CD3 Agonist, Cyclin Dependent Kinase 9 Inhibitor, Lysine Specific Histone Demethylase 1A (BRAF35 HDAC Complex Protein BHC110 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or [Histone H3]-Dimethyl-L-LysineInhibitor, B Cell Lymphoma 2 Inhibitor, and Bromodomain Containing Protein 4 Inhibitor
Routes of Administration Oral, Intravenous, Parenteral, Subcutaneous, Intratumor, Topical, Intradermal, Intralesional, Inhalational, and Intraperitoneal
Molecule Types Small Molecule, Gene-Modified Cell Therapy, Monoclonal Antibody, Cell Therapy, Monoclonal Antibody Conjugated, Fusion Protein, Synthetic Peptide, Subunit Vaccine, Antisense Oligonucleotide, and Aptamer
Key Companies Bristol-Myers Squibb Co, Les Laboratoires Servier SAS, Novartis AG, Pfizer Inc, AbbVie Inc, Ascentage Pharma Group International, Daiichi Sankyo Co Ltd, Johnson & Johnson, AstraZeneca Plc, and CSPC Pharmaceutical Group Ltd

This report provides:

  • A snapshot of the global therapeutic landscape of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia).
  • Reviews of pipeline therapeutics for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
  • Descriptive drug profiles for the pipeline products which include product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities.
  • Key players involved in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) therapeutics and enlists all their major and minor projects.
  • Assessment of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA), and molecule type.
  • All the dormant and discontinued pipeline projects.
  • Reviews of the latest news related to pipeline therapeutics for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia).

Reasons to Buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies.
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Identify and understand important and diverse types of therapeutics under development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia).
  • Identify potential new clients or partners in the target demographic.
  • Develop strategic initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics.
  • Devise corrective measures for pipeline projects by understanding Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Key Players

  • 4SC AG

    A. Menarini Industrie Farmaceutiche Riunite Srl

    AB Science SA

    AbbVie Inc

    AbTis Co Ltd

    Accro BioScience (Suzhou) Co Ltd

    Acrotech Biopharma LLC

    Actinium Pharmaceuticals Inc

    Actinobac Biomed Inc

    ADC Therapeutics SA

    ADCendo ApS

    Adlai Nortye Biopharma Co Ltd

    Advanced BioDesign

    Advenchen Laboratories LLC

    Aeglea BioTherapeutics Inc

    Affichem SA

    Affimed GmbH

    AGC Biologics SpA

    Agenus Inc

    AIkido Pharma Inc

    Aileron Therapeutics Inc

    AIMM Therapeutics BV

    Akeso Inc

    Allogene Therapeutics Inc

    ALX Oncology Holdings Inc

    Amgen Inc

    Amphivena Therapeutics Inc

    Amplia Therapeutics Ltd

    Angiocrine Bioscience Inc

    ANP Technologies Inc

    Antengene Corp Ltd

    Antisense Therapeutics Ltd

    AnyGen Co Ltd

    APIM Therapeutics AS

    Aprea Therapeutics Inc

    AptaBio Therapeutics Inc

    Aptevo Therapeutics Inc

    Aptose Biosciences Inc

    Aravive Inc

    Arcellx Inc

    Argenx SE

    Arog Pharmaceuticals Inc

    Arrien Pharmaceuticals LLC

    Ascentage Pharma Group International

    Aslan Pharmaceuticals Ltd

    Astellas Pharma Inc

    Astex Pharmaceuticals Inc

    AstraZeneca Plc

    Atara Biotherapeutics Inc

    Athenex Inc

    ATP Biopharm

    Aucentra Therapeutics Pty Ltd

    AUM Biosciences Pte Ltd

    Auransa Inc

    Aurigene Discovery Technologies Ltd

    Avidin Biotechnology Ltd

    AVROBIO Inc

    Avvinity Therapeutics Ltd

    BAKX Therapeutics Inc

    Bantam Pharmaceutical LLC

    Bayer AG

    BCI Pharma SA

    Beam Therapeutics Inc

    BeiGene Ltd

    Beijing Immunochina Pharmaceuticals Co Ltd

    Beijing Konruns Pharmaceutical Co Ltd

    Beijing Mabworks Biotech Co Ltd

    Bellicum Pharmaceuticals Inc

    BerGenBio ASA

    Beroni Group Ltd

    Betta Pharmaceuticals Co Ltd

    Bio-Cancer Treatment International Ltd

    Bio-Path Holdings Inc

    Biokine Therapeutics Ltd

    BioLineRx Ltd

    Biomea Fusion Inc

    BioMed Valley Discoveries Inc

    Bionomics Ltd

    BioSight Ltd

    Biosplice Therapeutics Inc

    BioTheryX Inc

    BioXcel Therapeutics Inc

    Bivictrix Therapeutics PLC

    bluebird bio Inc

    Blueprint Medicines Corp

    BlueSphere Bio Inc

    Boehringer Ingelheim International GmbH

    Boryung ViGenCell Inc

    BoYen Therapeutics Inc

    Bridge Medicines LLC

    BridGene Biosciences Inc

    Bristol-Myers Squibb Co

    Brooklyn ImmunoTherapeutics Inc

    C4 Therapeutics Inc

    Calithera Biosciences Inc

    Canqura Oncology AB

    Canthera Discovery

    Captor Therapeutics SA

    Carbiogene Therapeutics Co Ltd

    Cardiff Oncology Inc

    Caribou Biosciences Inc

    Carna Biosciences Inc

    Carrick Therapeutics Ltd

    Catalent Inc

    CellCentric Ltd

    Cellectis SA

    Cellerant Therapeutics Inc

    Cellipse SAS (Inactive)

    Celularity Inc

    Celyad Oncology SA

    Centessa Pharmaceuticals Plc

    Centrose LLC

    Centrymed Pharmaceutical Inc

    Century Therapeutics Inc

    Changzhou Qianhong Bio-Pharma Co Ltd

    CharlestonPharma LLC

    Checkpoint Therapeutics Inc

    Cheetah Cell Therapeutics Co Ltd

    Chimerix Inc

    China Immunotech (Beijing) Biotechnology Co Ltd

    Chongqing Precision Biotech Co Ltd

    Chordia Therapeutics Inc

    Chugai Pharmaceutical Co Ltd

    CicloMed LLC

    Clear Creek Bio Inc

    Cleave Therapeutics Inc

    Cogent Biosciences Inc

    CoImmune Inc

    Constellation Pharmaceuticals Inc

    CRISPR Therapeutics AG

    CrystalGenomics Inc

    CSPC Pharmaceutical Group Ltd

    CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co Ltd

    Cue Biopharma Inc

    Cullinan Oncology Inc

    Curacle Co Ltd

    CuronBiotech Inc

    Cyclacel Pharmaceuticals Inc

    CytoImmune Therapeutics Inc

    Cytovia Inc

    Cytovia Therapeutics Inc

    Daiichi Sankyo Co Ltd

    Dalriada Therapeutics Inc

    Delta-Fly Pharma Inc

    Demuris Ltd

    Denovo Biopharma LLC

    Deverra Therapeutics Inc

    Diaccurate

    Diatheva srl

    DiNonA Inc

    Dong Wha Pharma Co Ltd

    Dong-A ST Co Ltd

    Duet Therapeutics Inc

    Eisai Co Ltd

    Eli Lilly and Co

    Ellipses Pharma Ltd

    Elpis Biopharmaceuticals Corp

    Emercell SAS

    Eminent Biosciences

    EntreChem SL

    Enzyme by Design Inc

    Epigene Therapeutics Inc

    Epizyme Inc

    Escend Pharmaceuticals Inc

    Etern BioPharma Co Ltd

    ExCellThera Inc

    Exonate Ltd

    Expression Therapeutics Inc

    F. Hoffmann-La Roche Ltd

    Faron Pharmaceuticals Oy

    Fate Therapeutics Inc

    FibroGen Inc

    Fimecs Inc

    Flavocure Biotech LLC

    Foghorn Therapeutics Inc

    Forma Therapeutics Inc

    Fujifilm Holdings Corp

    Gadeta BV

    Gamida Cell Ltd

    GammaDelta Therapeutics Ltd

    GEMoaB Monoclonals GmbH

    Genentech USA Inc

    GeneScience Pharmaceuticals Co Ltd

    GenFleet Therapeutics (Shanghai) Inc

    Genmab AS

    Genosco Inc

    Genus Oncology LLC

    Geron Corp

    Gilead Sciences Inc

    GlaxoSmithKline Plc

    GlycoMimetics Inc

    Glycostem Therapeutics BV

    Golden Biotechnology Corp

    Greenfire Bio LLC

    GT Biopharma Inc

    Guangzhou Bio-gene Technology Co Ltd

    H3 Biomedicine Inc

    Hangzhou Bensheng Pharmaceutical Co Ltd

    Hanmi Pharmaceuticals Co Ltd

    Hebei Senlang Biotechnology Co Ltd

    HEC Pharma Co Ltd

    Hefei Cosource Pharmaceutical Inc

    Helocyte Biosciences Inc

    HemoGenyx Pharmaceuticals Plc

    HighPass Bio Inc

    Hillstream BioPharma Inc

    Hinova Pharmaceuticals Co Ltd

    Horizon Therapeutics Plc

    Hoth Therapeutics Inc

    Hoverink Biotechnologies Inc

    HRAIN Biotechnology Co Ltd

    Hunan Siweikang Therapeutics Ltd

    Hutchison MediPharma Ltd

    HUYA Bioscience International LLC

    Hybrigenics SA

    I-Mab

    iCell Gene Therapeutics LLC

    IGF Oncology LLC

    IGM Biosciences Inc

    Imago BioSciences Inc

    ImCheck Therapeutics SAS

    Immune Onc Therapeutics Inc

    Immune System Key Ltd

    ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd

    Immunicum AB

    ImmunityBio Inc

    ImmunoAct Pvt Ltd

    Immunocore Holdings Plc

    ImmunoGen Inc

    IN8bio Inc

    Inatherys

    Incyte Corp

    Inflection Biosciences Ltd

    Inmune Bio Inc

    Innate Pharma SA

    InnoCare Pharma Ltd

    InnoPharmaScreen Inc

    Innovation Pharmaceuticals Inc

    Innovent Biologics Inc

    Intellia Therapeutics Inc

    Interprotein Corp

    Intra-Immusg Pvt Ltd

    Invivoscribe Inc

    Io Therapeutics Inc

    Ipsen SA

    Isoprene Pharmaceuticals Inc

    Iterion Therapeutics Inc

    Jacobio Pharmaceuticals Group Co Ltd

    January Therapeutics Inc

    Jasper Therapeutics Inc

    Jazz Pharmaceuticals Plc

    Jeil Pharmaceutical Co Ltd

    Jiangsu Aidea Pharmaceutical Co Ltd

    Jiangsu Hengrui Medicine Co Ltd

    Jiangxi Shanxing Biotechnology Co Ltd

    Johnson & Johnson

    JSK Therapeutics Inc

    Jubilant Therapeutics Inc

    Juventas Cell Therapy Ltd

    JW Pharmaceutical Corp

    KAHR medical Ltd

    Kainos Medicine Inc

    Kartos Therapeutics Inc

    Karyopharm Therapeutics Inc

    KeViRX Inc

    Kiadis Pharma NV

    KinaRx LLC

    Kineta Inc

    Kintor Pharmaceutical Ltd

    KisoJi Biotechnology Inc

    Komipharm International Co Ltd

    Kronos Bio Inc

    Kura Oncology Inc

    Kurome Therapeutics Inc

    Kymera Therapeutics

  • Inc

    Lai Corporation Pty Ltd

    LAVA Therapeutics NV

    Lead Discovery Center GmbH

    Legend Biotech Corp

    LegoChem Biosciences Inc

    Les Laboratoires Servier SAS

    Leukos Biotech SL

    Lynk Pharmaceutical Hangzhou Co Ltd

    Mablink Bioscience

    Machavert Pharmaceuticals LLC

    MacroGenics Inc

    Magenta Therapeutics Inc

    Mana Therapeutics Inc

    Marker Therapeutics Inc

    Maxinovel Pharmaceuticals

    MedAbome Inc

    MediGene AG

    MEI Pharma Inc

    Merck & Co Inc

    Merck KGaA

    Meryx Inc

    Millennium Pharmaceuticals Inc

    Minneamrita Therapeutics LLC

    MiRx Pharmaceuticals LLC

    Mito BioPharm LLC

    Molecular Partners AG

    Molecular Templates Inc

    Molecules For Health Inc

    Moleculin Biotech Inc

    Morphiex Biotherapeutics Inc

    Multitude therapeutics Inc

    Mustang Bio Inc

    MyeloRx LLC

    Nanexa AB

    Nanjing Iaso Biotherapeutics Co Ltd

    Nanjing Sanhome Pharmaceutical Co Ltd

    Nanoligent SL

    NanoPharmaceuticals LLC

    NanoValent Pharmaceuticals Inc

    Nektar Therapeutics

    Nemucore Medical Innovations Inc

    Nerviano Medical Sciences SRL

    Newave Pharmaceutical Inc

    NexImmune Inc

    NextCure Inc

    Nkarta Inc

    Nohla Therapeutics Inc

    Northlake International LLC

    Novartis AG

    Novorex Inc

    Nuvation Bio Inc

    OHM Oncology

    Oita University Institute of Advanced Medicine Inc

    Omeros Corp

    OncoC4 Inc

    Oncolytics Biotech Inc

    OncoMyx Therapeutics Inc

    Oncopeptides AB

    OncoSynergy Inc

    OncoTartis Inc

    Oncotelic Therapeutics Inc

    Oncternal Therapeutics

    ONK Therapeutics Ltd

    Ono Pharmaceutical Co Ltd

    Opsyon

    Orano Med LLC

    Orca Biosystems Inc

    Oryzon Genomics SA

    Otsuka Pharmaceutical Co Ltd

    Oxford BioMedica Plc

    Oxstem Ltd

    Pacylex Pharmaceuticals Inc

    Paean Biotechnology Inc

    PeLeMed Co Ltd

    PendreaBio Inc

    Penrose Therapeutix LLC

    PentixaPharm GmbH

    PersonGen Biomedicine Suzhou Co Ltd

    Petra Pharma Corp

    Pfizer Inc

    Pharma Mar SA

    PharmCADD Co Ltd

    Pharos iBio Co Ltd

    Phebra Pty Ltd

    Phi Pharma SA

    PhoreMost Ltd

    Picobella LLC

    Pimera Inc

    PiNK Biopharma Ltd

    Pinotbio Inc

    Pinteon Therapeutics Inc

    Pleco Therapeutics BV

    Plexium Inc

    Plexxikon Inc

    Polaris Pharmaceuticals Inc

    Prelude Therapeutics Inc

    Prescient Therapeutics Ltd

    PRISM Pharma Co Ltd

    Promutech Pharmaceuticals Inc

    Protheragen Inc

    Provectus Biopharmaceuticals Inc

    Provention Bio Inc

    PTC Therapeutics Inc

    PYC Therapeutics Ltd

    Pyxis Oncology Inc

    Qilu Pharmaceutical Co Ltd

    Qualigen Therapeutics Inc

    Qurient Co Ltd

    Race Oncology Ltd

    Rafael Pharmaceuticals Inc

    Rain Therapeutics Inc

    Rasio Therapeutics Inc

    Rasna Therapeutics Inc

    Regenacy Pharmaceuticals LLC

    ReguGene Co Ltd

    Relevant Bio

    Remedy Plan Inc

    Rhizen Pharmaceuticals SA

    Rich Pharmaceuticals Inc

    Rubius Therapeutics Inc

    Ryvu Therapeutics SA

    SA Science Inc

    Salarius Pharmaceuticals Inc

    Samus Therapeutics Inc

    Sandhill Therapeutics Inc

    Sanofi

    Sapience Therapeutics Inc

    Sareum Holdings Plc

    Schrodinger Inc

    Seagen Inc

    SELLAS Life Sciences Group Inc

    Senhwa Biosciences Inc

    Senti Biosciences Inc

    SFA Therapeutics LLC

    Shanghai Fosun Pharmaceutical (Group) Co Ltd

    Shanghai icell Biotechnology Co Ltd

    Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd

    Shanghai YaKe Biotechnology Co Ltd

    Shattuck Labs Inc

    Shengke Pharmaceuticals (Jiangsu) Ltd

    Shenzhen Chipscreen Biosciences Co Ltd

    Shijiazhuang Yiling Pharmaceutical Co Ltd

    Sichuan Kelun Bio-Tech Pharmaceutical Co Ltd

    SideROS

    Sierra Oncology Inc

    SignalChem Lifesciences Corp

    Sino Biopharmaceutical Ltd

    SiNOPSEE Therapeutics Pte Ltd

    SL Bigen Co Ltd

    Smart Immune SAS

    Solasia Pharma KK

    Sorrento Therapeutics Inc

    SpecificiT Pharma Inc

    SphingoGene Inc

    Stelexis Therapeutics LLC

    Stemirna Therapeutics Ltd

    StingInn LLC

    Storm Therapeutics Ltd

    Sumitomo Dainippon Pharma Co Ltd

    Sumitomo Dainippon Pharma Oncology

  • Inc

    Surface Oncology Inc

    Sutro Biopharma Inc

    SuviCa Inc

    Suzhou Maximum Bio-tech Co Ltd

    Suzhou Zelgen Biopharmaceutical Co Ltd

    Synactix Pharmaceuticals Inc

    Syndax Pharmaceuticals Inc

    SYNIMMUNE GmbH

    Syros Pharmaceuticals Inc

    Systimmune Inc

    Tacitus Therapeutics Inc

    Taivex Therapeutics Inc

    Takara Bio Inc

    Takeda Pharmaceutical Co Ltd

    TC BioPharm Ltd

    TCR2 Therapeutics Inc

    TeamedOn International Inc

    Telios Pharma Inc

    Telix Pharmaceuticals Ltd

    Tetranov International Inc

    Teva Pharmaceutical Industries Ltd

    Tiziana Life Sciences Plc

    Toko Pharmaceutical Industries Co Ltd

    TOLREMO Therapeutics AG

    TOT Biopharm Co Ltd

    TransThera Sciences (Nanjing) Inc

    Treadwell Therapeutics Inc

    Triphase Accelerator Corp

    TScan Therapeutics Inc

    TSD Life Sciences

    UbiVac LLC

    Vertex Pharmaceuticals Inc

    Veru Inc

    Vessel Scientific LLC

    Vichem Chemie Research Ltd

    Vincerx Pharma Inc

    VioQuest Pharmaceuticals Inc (Inactive)

    Viracta Therapeutics Inc

    Viralytics Pty Ltd

    Viridian Therapeutics Inc

    VM Discovery Inc

    Vor BioPharma Inc

    Vyriad Inc

    Wellington Zhaotai Therapies Ltd

    Wigen Biomedicine Technology (Shanghai) Co Ltd

    Wugen Inc

    Wuhan Bio-Raid Biotechnology Co Ltd

    Wyze Biotech Co Ltd

    XEME BioPharma Inc

    Xencor Inc

    XNK Therapeutics AB

    Y-mAbs Therapeutics Inc

    Yungjin Pharm Co Ltd

    Zenith Epigenetics Ltd

    Zentalis Pharmaceuticals Inc

    Zhengda Tianqing Pharmaceutical Group Co Ltd

    ZIOPHARM Oncology Inc

    Zovis Pharmaceuticals

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Overview

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Companies Involved in Therapeutics Development

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Drug Profiles

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Dormant Projects

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Discontinued Products

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Product Development Milestones

Featured News & Press Releases

Appendix

Methodol’ogy

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Products under Development by Companies, 2021

Products under Development by Universities/Institutes, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Dormant Projects, 2021

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Number of Products by Top 10 Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Top 10 Mechanism of Actions, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Top 10 Routes of Administration, 2021

Number of Products by Stage and Top 10 Routes of Administration, 2021

Number of Products by Top 10 Molecule Types, 2021

Number of Products by Stage and Top 10 Molecule Types, 2021

Frequently Asked Questions

$2500

Can be used by individual purchaser only

$7500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.